Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer [0.03%]
聚焦于曲妥珠单抗德鲁特坎（DS-8201，T-DXd）在HER2突变阳性非小细胞肺癌中的应用
Ibrahim Azar,Samer Alkassis,Jami Fukui et al.
Ibrahim Azar et al.
Human epidermal growth factor receptor 2 (HER2) is a proto-oncogene that, when mutated or overexpressed, plays an important role in oncogenesis. The landscape of HER2-positive breast cancer has changed dramatically over the past 2 decades w...
An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece [0.03%]
希腊真实世界临床环境中，阿法替尼治疗晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌患者的分子流行病学和直接医疗费用评估观察性研究
Giannis Mountzios,Sofia Lampaki,Georgia-Angeliki Koliou et al.
Giannis Mountzios et al.
Purpose: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred first-line option for patients with advanced, EGFR-mutant non-small cell lung cancer (NSCLC). Afatinib, a second-generat...
An Update on the Use of Exhaled Breath Analysis for the Early Detection of Lung Cancer [0.03%]
呼出气分析在肺癌早期诊断中的应用进展
Nir Peled,Vered Fuchs,Emily H Kestenbaum et al.
Nir Peled et al.
Lung cancer has historically been the main responsible for cancer associated deaths. Owing to this is our current inability to screen for and diagnose early pathological findings, preventing us from a timely intervention when cure is still ...
Targeting AXL in NSCLC [0.03%]
靶向AXL以治疗非小细胞肺癌
Aubhishek Zaman,Trever G Bivona
Aubhishek Zaman
State-of-the-art cancer precision medicine approaches involve targeted inactivation of chemically and immunologically addressable vulnerabilities that often yield impressive initial anti-tumor responses in patients. Nonetheless, these respo...
Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges [0.03%]
MET第14外显子跳跃突变型肺癌的遗传特征、现有疗法及未来挑战
Toshio Fujino,Kenichi Suda,Tetsuya Mitsudomi
Toshio Fujino
MET exon 14 skipping mutation (MET∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency...
Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations [0.03%]
莫博赛替尼(TAK-788)治疗EGFR 20号外显子插入突变非小细胞肺癌盘点
Shannon S Zhang,Viola W Zhu
Shannon S Zhang
The EGFR exon 20 insertion (EGFRex20ins) mutations are the third most common EGFR mutations seen in non-small cell lung cancer (NSCLC). More than 50 variants of EGFRex20ins mutations have been identified with A767_V769dupASV being the most ...
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer [0.03%]
早期非小细胞肺癌的术前和术后免疫治疗
Nikhil Shukla,Nasser Hanna
Nikhil Shukla
Surgery or concurrent chemoradiation are standard of care treatments for patients with localized and locally advanced non-small cell lung cancer (NSCLC). While resection and chemoradiation are potentially curative therapies for early-stage ...
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs) [0.03%]
免疫检查点抑制剂治疗非小细胞肺癌(NSCLC)的预后和预测生物标志物识别
Nicholas Giustini,Lyudmila Bazhenova
Nicholas Giustini
Immunotherapy plays a central role in the treatment of NSCLC and biomarkers predicting response to ICIs are valuable therapeutic tools. Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) is integral in therapy selection as its pos...
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib [0.03%]
用于MET外显子14跳变型转移性非小细胞肺癌的新疗法——关注卡马替尼疗效
Aaron C Tan,Tracy J Loh,Xue Lin Kwang et al.
Aaron C Tan et al.
MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demons...
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling [0.03%]
通过联合靶向MEK/ERK信号来管理第三代EGFR酪氨酸激酶抑制剂获得性耐药的方法
Danlei Yu,Wen Zhao,Karin A Vallega et al.
Danlei Yu et al.
Although epidermal growth factor receptor (EGFR)-targeted therapy has improved clinical outcomes of patients with advanced non-small-cell lung cancer (NSCLC) carrying activating EGFR mutations, the development of acquired resistance to EGFR...